Sugammadex + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
General Surgery
Conditions
General Surgery
Trial Timeline
Jun 1, 2016 โ Dec 1, 2019
NCT ID
NCT02728726About Sugammadex + Placebo
Sugammadex + Placebo is a approved stage product being developed by Merck for General Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02728726. Target conditions include General Surgery.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02728726 | Approved | Completed |
| NCT02028065 | Phase 1 | Completed |
| NCT00591409 | Phase 2 | Completed |
| NCT00379613 | Phase 2 | Completed |
Competing Products
20 competing products in General Surgery